期刊文献+

脑胶质瘤中表皮生长因子受体磷酸化AKT的表达及临床意义 被引量:2

Epressions and clinical significance of EGFR and PAKT in glioma
原文传递
导出
摘要 目的探讨不同病理级别脑胶质瘤中表皮生长因子受体(EGFR)及磷酸化AKT(PAKT)的表达及临床意义。方法收集经手术切除的65例脑胶质瘤标本和5例正常脑组织,行免疫组织化学方法染色,检测EGFR与PAKT表达水平。结果脑胶质瘤组织中EGFR和PAKT的阳性表达率分别为73.84%和63.08%;EGFR和PAKT在Ⅲ~Ⅳ级脑胶质瘤的表达率为80.85%和72.34%,均显著高于工~Ⅱ级的55.56%和38.89%(P〈0.05)。EGFR与PAKT的表达水平呈正相关(r=O.68,P〈0.01)。结论EGFR与PAKT在脑胶质瘤中存在过表达与共表达,且与胶质瘤的恶性程度相关;检测两者表达水平对胶质瘤的早期诊断、靶向治疗及预测患者的预后有重要价值。 Objective To investgate the expressions and clinical significance of epithilial growth factor receptor(EGFR) and phosphorylated AKT(PAKT) in different histological grades of glioma. Methods Human glioma samples were collected from surgical patients. Immunohistochemical staining was performed and the expressions of EGFR and PAKT were detected. Results The positive rates of EGFR and PAKT expressions in glioma patients were 76.60% and 72.34% ,respectively,which were higher in grdes of Ⅲ~Ⅳ glioma than in grades of I~Ⅱ(80.85% and 72.34% vs 55.56% and 38. 89%)(P〈0.05). There was a positive linear correlation between EGFR and PAKT expressions (r=O. 8761,P〈0. 01). Conclusion Overexpression and coexpression of EGFR and PAKT exist in glioma,which are related to tumor malignacy. Decting their expression levels is significant in early diagnosis.targeted theraov and nredieting nrngnngis of tho nationts with grlinmn
出处 《江苏医药》 CAS CSCD 北大核心 2011年第8期937-939,F0003,共4页 Jiangsu Medical Journal
关键词 脑胶质瘤 表皮生长因子受体 磷酸化AKT Glioma Epithilial growth factor receptor Phosphorylated
  • 相关文献

参考文献10

  • 1Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics[J].Mol Cancer, 2010,9 : 135.
  • 2Kang CS, Zhang ZY, Jia ZF,et at. Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo[J]. Cancer Gene Ther, 2006,13 (5) : 530-538.
  • 3康春生,浦佩玉,李捷,于士柱,王虎,江荣才,董伦,王广秀.人脑胶质瘤EGFRAKT通路活性的研究[J].中国临床神经科学,2004,12(2):109-112. 被引量:10
  • 4Harris RC, Chung E, Coffey RJ, et al.EGF receptor ligands[J]. Exp Cell Res,2003,284(1):2-13.
  • 5Mukherjee B, McEllin B, Camacho CV, et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistancein glioblastoma[J]. Cancer Res,2009,69(10) 4252-4259.
  • 6韩磊,浦佩玉,康春生.脑胶质瘤PI3K信号通路的研究进展[J].中国神经肿瘤杂志,2010,8(1):39-43. 被引量:3
  • 7Mizoguchi M, Betensky RA, Batchelor TT, et al. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival[J].J Neuropathol Exp Neurol,2006,65(12):1181-1188.
  • 8Suzuki Y, Shirai K, Oka K, et al. Higher pAkt expression predicts a significant worse prognosis in glioblastomas[J].J Radiat Res(Tokyo), 2010,51 (3) : 343-348.
  • 9Caldera V, Mellai M, Annovazzi L, et al. Stat3 expression and its correlation with proliferation and apoptosis/autophagy in gliomas[J]. J Oncol, 2008,2008:219241.
  • 10Stommel JM,Kimmelman AC,Ying H,et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies[J]. Science,2007,318(5848):287-290.

二级参考文献2

共引文献11

同被引文献38

  • 1苗丽君,王静,李珊珊,吴逸明,吴拥军.磷酸化AKT及Cyclin D1、MMP-9在非小细胞肺癌中的表达及相关性研究[J].中国现代医学杂志,2007,17(7):786-790. 被引量:4
  • 2步宏,郑杰.美国临床肿瘤学会/美国病理学医师学院乳腺癌HER2检测指南简介[J].中华病理学杂志,2007,36(7):496-497. 被引量:24
  • 3Zhang J, Zhang QY, Fu YC, et al. Expression of p Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Aktl and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcino- ma and U251 glioma cell growth in vitro and in vivo [J]. Techn- ol Cancer Res Treat,2009, 8(6) :467-478.
  • 4Cheng X, Xia W, Yang JY, et al. Activation of murine double minute 2 by Akt in mammary epithelium delays mammary invo- lution and accelerates mammary tumorigenesis [J]. Cancer Res, 2010,70(19) :7684-7689.
  • 5Jiang P, Enomoto A, Takahashi M. Cell biology of the move- ment of breast cancer cells:intracellular signalling and the actin cytoskeleton[J]. Cancer Lett, 2009, 284(2) :122-130.
  • 6Tokunaga E, Kimura Y,Oki E, et al. Akt is frequently activa- ted in HER-2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients [J]. Int J Canc- er, 2006, 118(2) :284-289.
  • 7Aleskandarany MA, Rakha EA, Ahmed MA, et al. Clinico- pathologic and molecular significance of phospho-Akt expression in early invasive breast cancer [J]. Breast Cancer Res Treat, 2010,127(2) :407-416.
  • 8Harvey J, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-hinding assay for predicting response to adjuvant endocrine therapy in breast cancer [J]. J Clin Oncol, 1999,17:1474-1481.
  • 9Benesch C, Schneider C, Voelker HU, et al. The clinicopatho- logical and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer [J]. Anticancer Res, 2010, 30(5): 1689-1694.
  • 10Yu P, Zhou L, Ke W, et al. Clinical significance of pAkt and CD44v6 overexpression with breast cancer [J]. J Cancer Res Clin Oncol, 2010,136(8) :1283-1292.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部